Matches in SemOpenAlex for { <https://semopenalex.org/work/W4234380984> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4234380984 endingPage "929" @default.
- W4234380984 startingPage "929" @default.
- W4234380984 abstract "Olanzapine is one of the newer atypical antipsychotic agents which is being increasingly used, as it is effective in the maintenance treatment of chronic schizophrenia. A 33-year-old man was recently admitted to the intensive care unit following an overdose of 30 tablets of olanzapine with an initial Glasgow Coma Scale (GCS) of 15. Over a period of 30–40 min the patient developed continuous vomiting and the GCS deteriorated to 7. Further examination revealed a heart rate of 136 beats. min−1, a respiratory rate of 16 min−1, a blood pressure of 170/110 mmHg and bilaterally constricted pupils. There was no response to a dose of naloxone. Oxygen saturation and arterial blood gases were unremarkable. The patient was intubated and ventilated in view of persistent vomiting and a deteriorating level of consciousness. On arrival at the intensive care unit the patient was stable with normal ECG, clotting screen and creatinine kinase; urine was negative for myoglobin. The patient was ventilated overnight and extubated the following day without complication and made a good recovery. During the admission of this patient, the Poisons Information Centre was contacted for information regarding the potential problems of toxicity with olanzapine. As this agent is relatively new with few reported cases of overdose with which to refer, the effects of toxicity were not clearly defined. The following were suggested as possible toxic effects and are likely to be extrapolated from other similar drugs: CNS depression, convulsions and coma, prolonged QT interval and a-v block, hypotension and the development of neuroleptic malignant syndrome. Of these, the patient had only CNS depression, with hypertension rather than hypotension. Marked vomiting and bilateral pupillary constriction were also a feature. The increasing use of olanzapine in the maintenance treatment of chronic schizophrenia will inevitably result in an increase in the incidence of cases of overdose in this high-risk group of patients. As little is yet known about the effects of this agent in toxic doses, it is important that features of overdose are noted and further cases reported in order to develop a toxicity profile of this drug and to establish the management of overdose." @default.
- W4234380984 created "2022-05-12" @default.
- W4234380984 creator A5018242055 @default.
- W4234380984 creator A5032892064 @default.
- W4234380984 date "2000-09-26" @default.
- W4234380984 modified "2023-09-30" @default.
- W4234380984 title "Olanzopine overdose" @default.
- W4234380984 doi "https://doi.org/10.1046/j.1365-2044.2000.01664-25.x" @default.
- W4234380984 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10947781" @default.
- W4234380984 hasPublicationYear "2000" @default.
- W4234380984 type Work @default.
- W4234380984 citedByCount "8" @default.
- W4234380984 countsByYear W42343809842022 @default.
- W4234380984 crossrefType "journal-article" @default.
- W4234380984 hasAuthorship W4234380984A5018242055 @default.
- W4234380984 hasAuthorship W4234380984A5032892064 @default.
- W4234380984 hasBestOaLocation W42343809841 @default.
- W4234380984 hasConcept C100136789 @default.
- W4234380984 hasConcept C118552586 @default.
- W4234380984 hasConcept C120665830 @default.
- W4234380984 hasConcept C121332964 @default.
- W4234380984 hasConcept C126322002 @default.
- W4234380984 hasConcept C17624336 @default.
- W4234380984 hasConcept C177713679 @default.
- W4234380984 hasConcept C2776376669 @default.
- W4234380984 hasConcept C2776412080 @default.
- W4234380984 hasConcept C2776619155 @default.
- W4234380984 hasConcept C2777953023 @default.
- W4234380984 hasConcept C2780852908 @default.
- W4234380984 hasConcept C2987404301 @default.
- W4234380984 hasConcept C42219234 @default.
- W4234380984 hasConcept C71924100 @default.
- W4234380984 hasConcept C8213797 @default.
- W4234380984 hasConcept C84393581 @default.
- W4234380984 hasConceptScore W4234380984C100136789 @default.
- W4234380984 hasConceptScore W4234380984C118552586 @default.
- W4234380984 hasConceptScore W4234380984C120665830 @default.
- W4234380984 hasConceptScore W4234380984C121332964 @default.
- W4234380984 hasConceptScore W4234380984C126322002 @default.
- W4234380984 hasConceptScore W4234380984C17624336 @default.
- W4234380984 hasConceptScore W4234380984C177713679 @default.
- W4234380984 hasConceptScore W4234380984C2776376669 @default.
- W4234380984 hasConceptScore W4234380984C2776412080 @default.
- W4234380984 hasConceptScore W4234380984C2776619155 @default.
- W4234380984 hasConceptScore W4234380984C2777953023 @default.
- W4234380984 hasConceptScore W4234380984C2780852908 @default.
- W4234380984 hasConceptScore W4234380984C2987404301 @default.
- W4234380984 hasConceptScore W4234380984C42219234 @default.
- W4234380984 hasConceptScore W4234380984C71924100 @default.
- W4234380984 hasConceptScore W4234380984C8213797 @default.
- W4234380984 hasConceptScore W4234380984C84393581 @default.
- W4234380984 hasIssue "9" @default.
- W4234380984 hasLocation W42343809841 @default.
- W4234380984 hasLocation W42343809842 @default.
- W4234380984 hasOpenAccess W4234380984 @default.
- W4234380984 hasPrimaryLocation W42343809841 @default.
- W4234380984 hasRelatedWork W1967567453 @default.
- W4234380984 hasRelatedWork W1979334705 @default.
- W4234380984 hasRelatedWork W2034790546 @default.
- W4234380984 hasRelatedWork W2071651339 @default.
- W4234380984 hasRelatedWork W2148279087 @default.
- W4234380984 hasRelatedWork W2158034487 @default.
- W4234380984 hasRelatedWork W2375807291 @default.
- W4234380984 hasRelatedWork W2611183031 @default.
- W4234380984 hasRelatedWork W2901246318 @default.
- W4234380984 hasRelatedWork W3195885893 @default.
- W4234380984 hasVolume "55" @default.
- W4234380984 isParatext "false" @default.
- W4234380984 isRetracted "false" @default.
- W4234380984 workType "article" @default.